Fed signals rate cuts by September amidst macro risks and tensions. Click for what this may mean for AT&T Inc. and T ...

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

Nuvation Bio's FDA approval for IBTROZI isn't boosting its stock. Learn about NUVB's financial risks, valuation concerns, and ...

Analysts have to remember that the Federal Reserve is operating under a different set of parameters than in previous times.

AMLP offers direct exposure to US midstream operators with an attractive 8% yield, benefiting from owning stable, ...

Yesterday, the NAHB published its latest monthly update on homebuilder sentiment. The headline sentiment index continued to ...

Aurora Cannabis faces headwinds as Q4/FY2025 revenues grow but profitability declines due to one-time expenses. Check out why ...

BRSP's dividend yield is attractive at 12.4%, but coverage is thin, and another cut is likely. Click here to find out why ...

SAFX is a clear short due to desperate deal terms, no cash, and potential insider selling enabled by lock-up waivers. Click ...

SCHA's high valuations and limited earnings growth make it less appealing for value investors. Find out why SCHA is not an ...

FSCO's portfolio is 73% private debt and 69% floating rate, providing resilience against market volatility and rising rates.

Meta Platforms' WhatsApp announcement adds another catalyst for growth and appreciation. Click here to find out why I rate ...